Protein A Resin Market is Predicted to See Lucrative Gains Over 2021-2025
Growing demand for disposable pre-packed columns, rising need for therapeutic antibodies, and rising pharmaceutical R&D spending are projected to fuel market expansion over the forecast period. The high cost of resins, on the other hand, is projected to impede the market's expansion.
The protein A resin market is predicted to grow at a CAGR of 11.4 percent from USD 1.1
billion in 2020 to USD 1.9 billion in 2025. Monoclonal antibodies have
revolutionised the way we treat a variety of diseases over the last 30 years,
proving to be more effective, well tolerated, and easier to administer than
other treatments. Monoclonal antibodies may be able to help prevent and treat
early COVID-19 infections, according to researchers. Several monoclonal
antibodies for different disorders have been approved or are in development.
One of these is adalimumab, which is used to treat arthritis and Crohn's
disease. The COVID-19 Therapeutics Accelerator recently financed a trial at the
University of Oxford to see if it may be used to treat patients in care homes.
In June 2020, Eli Lilly and Company (US) and AbCellera (Canada) initiated the
first human research of a potential COVID-19 antibody therapy. Because protein
A resin is essential for the purification of antibodies, the current pandemic's
increase in mAb manufacturing is expected to boost the protein A resin market.
A growing number of contract manufacturing organisations (CMOs) and contract research organisations (CROs) are offering their services to pharmaceutical businesses all over the world. During the projected period, this is expected to provide prospective growth opportunities for protein A resin makers.
In numerous
fields of research, pharmaceutical companies are increasingly relying on contract
manufacturers to meet a variety of basic demands, such as specialised
competence. In recent years, the pharmaceutical contract manufacturing business
has seen strong expansion, and this trend is projected to continue in the
future. Core pharmaceutical firms have been forced to rely on contract
manufacturing as a result of increased government pressure to cut healthcare
costs and deteriorating R&D productivity. Furthermore, China's growing
demand for generic pharmaceuticals
Geographically,
North America is predicted to lead the worldwide protein A resin market in
2019, with Asia Pacific expected to grow at the fastest rate over the forecast
period. As APAC has emerged as a prominent pharmaceutical and biopharmaceutical
research hub, the region's rapid growth can be linked to increased R&D
activity. As a result, a number of major pharmaceutical and biopharmaceutical
firms have established research facilities in the area. Local significant firms
including Ranbaxy, Dr. Reddy's, Cipla, Lupin, and Cadila are also actively
participating in biosimilar and generic medicine research.
Some of the
key players in the protein A resin market are GE Healthcare (US), Repligen
Corporation (US), and Merck Millipore (Germany).

Comments
Post a Comment